The brain's receptors: a field guide
How receptors turn a neurotransmitter into an effect: the two designs, the main families, what each does, and the medicines that act on them.
A neurotransmitter has no meaning until a receptor reads it. The receptor decides whether a signal excites or inhibits, whether it lasts a millisecond or a minute, and which cells respond at all.
This is why one transmitter can do opposite things. Acetylcholine contracts skeletal muscle and slows the heart. Dopamine starts a movement through one receptor and restrains it through another. The difference is the receptor.
Receptors are also where medicine is most precise. A transporter or enzyme drug changes the level of a transmitter everywhere. A receptor drug can change one of its effects and leave the others alone.
#How this list was prioritized
The brain has several hundred receptor types. This post covers the families that matter most, ranked by impact: how much of brain function runs through them, and how many medicines act on them.
- Glutamate and GABA receptors come first. They carry nearly all fast signalling.
- Dopamine, serotonin, adrenergic and acetylcholine receptors come next. Most psychiatric medicines act here.
- Histamine and opioid receptors follow, then a short list of others worth knowing.
Each section is self-contained and follows the same order: the subtypes, how they work, what they do, what goes wrong, and the medicines that act on them.
This post is one of three. The companion posts cover the neurotransmitters these receptors read and the transporters that clear them.
#The two designs
Every neurotransmitter receptor is one of two kinds. Knowing which kind tells you its speed, its duration and how drugs can act on it.
| Ion-channel receptors (ionotropic) | G-protein receptors (metabotropic) | |
|---|---|---|
| What it is | A channel that opens when transmitter binds | A sensor that activates a G protein inside the cell |
| Speed | Under a millisecond | Tenths of a second to minutes |
| Effect | Ions flow and voltage changes at once | Second messengers change channels, enzymes and gene activity |
| Amplification | None: one receptor, one channel | Large: one receptor activates many G proteins |
| Examples | AMPA, NMDA, GABA-A, nicotinic, 5-HT3, glycine | All dopamine, adrenergic, muscarinic, opioid and most serotonin receptors |
#The three G proteins
A G-protein receptor's effect depends on which G protein it couples to. Three families cover nearly every receptor in this post.
| G protein | What it does inside the cell | Net effect | Receptors that use it |
|---|---|---|---|
| Gs | Raises cAMP | Activating | D1, D5, beta-adrenergic, H2, 5-HT4, 5-HT6, 5-HT7 |
| Gi | Lowers cAMP, opens potassium channels, closes calcium channels | Quieting | D2, D3, D4, alpha-2, 5-HT1, GABA-B, opioid, M2, M4, CB1 |
| Gq | Releases calcium from internal stores | Activating | Alpha-1, 5-HT2, M1, M3, M5, H1 |
#How drugs act on a receptor
| Term | Meaning | Example |
|---|---|---|
| Agonist | Activates the receptor fully | Pramipexole at dopamine D2 and D3 |
| Partial agonist | Activates it weakly. Raises low signalling and caps high signalling. | Aripiprazole at D2 |
| Antagonist | Occupies the receptor and blocks the transmitter, with no effect of its own | Haloperidol at D2 |
| Inverse agonist | Reduces the receptor's activity below its resting level | Pimavanserin at 5-HT2A |
| Allosteric modulator | Binds a second site and turns the transmitter's effect up or down | Benzodiazepines at GABA-A |
#Where a receptor sits
- Postsynaptic receptors sit on the receiving cell and carry the signal forward.
- Autoreceptors sit on the releasing cell and detect its own transmitter. They act as a brake on further release.
- Extrasynaptic receptors sit away from synapses and respond to low background levels of transmitter.
#Receptors adapt
Receptor numbers are not fixed. Sustained stimulation makes cells remove receptors or uncouple them. Sustained blockade makes cells add more. This adaptation underlies tolerance, withdrawal effects when a medicine is stopped abruptly, and the delayed onset of many psychiatric treatments.
#Map at a glance
Every receptor family in this post, in the order it appears. Rows are sorted by impact, highest first.
| Transmitter | Receptor | Design | Main effect | Medicines that act on it |
|---|---|---|---|---|
| Glutamate | AMPA | Ion channel | Fast excitation | Perampanel |
| Glutamate | NMDA | Ion channel | Learning, plasticity | Esketamine, memantine |
| Glutamate | mGluR1 to mGluR8 | G protein | Fine-tunes excitation | None approved |
| GABA | GABA-A | Ion channel | Fast inhibition | Benzodiazepines, zolpidem, propofol, zuranolone |
| GABA | GABA-B | G protein, Gi | Slow inhibition | Baclofen |
| Dopamine | D1, D5 | G protein, Gs | Promotes action, working memory | None selective in wide use |
| Dopamine | D2, D3, D4 | G protein, Gi | Restrains action; autoreceptor | Antipsychotics, pramipexole, aripiprazole |
| Serotonin | 5-HT1A | G protein, Gi | Calming; autoreceptor | Buspirone |
| Serotonin | 5-HT1B, 5-HT1D | G protein, Gi | Reduces transmitter release | Triptans |
| Serotonin | 5-HT2A | G protein, Gq | Excites cortex | Second-generation antipsychotics, pimavanserin |
| Serotonin | 5-HT3 | Ion channel | Nausea, gut reflexes | Ondansetron |
| Noradrenaline | Alpha-1 | G protein, Gq | Arousal, vessel constriction | Prazosin |
| Noradrenaline | Alpha-2 | G protein, Gi | Brake on release; prefrontal focus | Clonidine, guanfacine |
| Noradrenaline | Beta | G protein, Gs | Heart rate, emotional memory | Propranolol |
| Acetylcholine | Nicotinic | Ion channel | Muscle contraction, attention | Varenicline |
| Acetylcholine | Muscarinic M1 to M5 | G protein | Memory, parasympathetic control | Xanomeline; many anticholinergics |
| Histamine | H1 | G protein, Gq | Wakefulness | Antihistamines |
| Histamine | H3 | G protein, Gi | Autoreceptor | Pitolisant |
| Opioid peptides | Mu, delta, kappa | G protein, Gi | Pain relief, reward | Opioid pain medicines, naloxone, buprenorphine |
| Adenosine | A1, A2A | G protein | Sleep pressure | Caffeine blocks both |
| Orexin | OX1, OX2 | G protein | Stable wakefulness | Suvorexant, lemborexant, daridorexant |
| Melatonin | MT1, MT2 | G protein, Gi | Body clock timing | Melatonin, ramelteon |
#Glutamate receptors
Glutamate receptors carry the brain's excitation and store its memories. Two ion-channel types do the main work as a pair: AMPA receptors pass the signal, and NMDA receptors decide whether the synapse should be strengthened.
#The subtypes
| Receptor | Design | Lets in | Role |
|---|---|---|---|
| AMPA | Ion channel | Sodium | Fast excitation at nearly every excitatory synapse |
| NMDA | Ion channel | Sodium and calcium | Detects coincident activity and triggers plasticity |
| Kainate | Ion channel | Sodium | Adjusts release and excitability; least understood |
| mGluR1, mGluR5 | G protein, Gq | Raise excitability, on the receiving cell | |
| mGluR2, mGluR3 | G protein, Gi | Brake on glutamate release, on the sending cell | |
| mGluR4, 6, 7, 8 | G protein, Gi | Brake on release; mGluR6 is used in the retina |
#How the AMPA and NMDA pair works
- Glutamate binds both receptors.
- The AMPA receptor opens at once and excites the cell.
- The NMDA receptor stays blocked by a magnesium ion sitting in its pore.
- If the cell is already excited enough, the magnesium is pushed out and the NMDA receptor opens.
- Calcium enters and signals the cell to add more AMPA receptors to that synapse.
The NMDA receptor therefore opens only when sending and receiving cells are active together. A synapse with more AMPA receptors responds more strongly next time. This is long-term potentiation, the best-studied cellular basis of learning.
The NMDA receptor also needs a second molecule, glycine or D-serine, bound at a separate site before it can open.
#When it goes wrong
- Excitotoxicity. Prolonged NMDA receptor opening admits too much calcium and kills neurons. This occurs in stroke and brain injury.
- Anti-NMDA receptor encephalitis. Antibodies remove NMDA receptors from the cell surface. Patients develop psychosis, memory loss, seizures and movement disorders, and usually recover with immune treatment.
- Schizophrenia. Reduced NMDA receptor function is a leading model, supported by genetics and by the encephalitis above.
- Developmental disorders. Mutations in NMDA receptor genes cause epilepsy and intellectual disability.
#Medicines
- Esketamine blocks the NMDA receptor pore. It relieves treatment-resistant depression within hours to days, far faster than standard antidepressants.
- Dextromethorphan with bupropion is an oral NMDA receptor blocker approved for depression.
- Memantine blocks the pore weakly and briefly, which dampens excess activity while sparing normal signalling. It is used in Alzheimer's disease.
- Perampanel blocks AMPA receptors and is used in epilepsy.
Drugs acting on metabotropic glutamate receptors have been tested in schizophrenia and fragile X syndrome. None has succeeded in large trials.
#GABA receptors
GABA receptors are the brain's inhibition. GABA-A is the most heavily medicated receptor in the brain: sedatives, sleep medicines, anaesthetics and many anti-seizure drugs all act on it.
#The two types
| GABA-A | GABA-B | |
|---|---|---|
| Design | Ion channel | G protein, Gi |
| Lets through | Chloride, inward | Opens potassium channels, closes calcium channels |
| Speed | Milliseconds | Hundreds of milliseconds |
| Effect | Holds the cell below its firing threshold | Slow, lasting inhibition and less transmitter release |
| Main medicine | Benzodiazepines | Baclofen |
#GABA-A: a receptor built from parts
A GABA-A receptor is assembled from five subunits chosen from 19 possible kinds. The mix determines where it sits, how it behaves and which drugs affect it.
| Subunit present | Where | Linked effect |
|---|---|---|
| Alpha-1 | Throughout the brain, at synapses | Sedation |
| Alpha-2, alpha-3 | Amygdala, cortex, spinal cord | Relief of anxiety, muscle relaxation |
| Alpha-5 | Hippocampus | Memory impairment |
| Delta | Outside synapses | Steady background inhibition; sensitive to neurosteroids |
This is why the search for an anxiety medicine without sedation has focused on drugs that prefer alpha-2 and alpha-3.
#How the main drugs act
None of these opens the receptor in the normal way. Each binds its own site and changes how the receptor responds to GABA.
- Benzodiazepines make the channel open more often when GABA is present. They do little without GABA, which limits their effect when taken alone.
- Zolpidem and related sleep medicines bind the same site but prefer alpha-1 receptors.
- Barbiturates and propofol hold the channel open longer and, at high doses, open it without GABA. This is why they can produce anaesthesia.
- Neurosteroids such as zuranolone act on synaptic and extrasynaptic receptors. They are used for postpartum depression.
- Flumazenil blocks the benzodiazepine site and reverses benzodiazepine effects.
#When it goes wrong
- Epilepsy. Mutations in GABA-A subunit genes cause several inherited epilepsies.
- Tolerance and dependence. With weeks of daily benzodiazepine use, receptors adapt. Stopping abruptly can cause rebound anxiety, insomnia and seizures, so doses are reduced gradually.
- Postpartum depression. Levels of the natural neurosteroid allopregnanolone fall sharply after birth. This is the reasoning behind neurosteroid treatment.
#GABA-B
GABA-B receptors sit on both sides of the synapse. On the sending side they reduce transmitter release. On the receiving side they produce a slow inhibition. Baclofen activates them and is used to relieve spasticity.
#Dopamine receptors
Dopamine has five receptors in two families with opposite effects. The D2 receptor is the central target in the treatment of psychosis: every established antipsychotic acts on it.
#The two families
| Family | Members | G protein | Effect on the cell | Mainly found in |
|---|---|---|---|---|
| D1-like | D1, D5 | Gs | Activating | Striatum, prefrontal cortex |
| D2-like | D2, D3, D4 | Gi | Quieting | Striatum, limbic areas, pituitary; D4 in cortex |
#What they do
- Movement: go and no-go. The striatum has two output pathways. The direct pathway carries D1 receptors and promotes action. The indirect pathway carries D2 receptors and suppresses action. Dopamine excites the first and quiets the second, so it favours movement through both.
- Working memory. Prefrontal D1 receptors hold information in mind. Function is best at moderate stimulation and falls off with too little or too much.
- Self-regulation. D2 autoreceptors on dopamine neurons slow firing and release when dopamine rises.
- Motivation. D3 receptors are concentrated in limbic parts of the striatum that handle reward.
- Hormones and nausea. D2 receptors in the pituitary hold back prolactin. D2 receptors in the brainstem trigger vomiting.
#D2 and antipsychotics
The clinical strength of the older antipsychotics tracks how tightly they bind D2. Imaging studies then defined a working range.
| Share of D2 receptors blocked | What is typically seen |
|---|---|
| Below about 60% | Often too little antipsychotic effect |
| About 65% to 80% | Antipsychotic effect |
| Above about 80% | Stiffness, tremor, restlessness and raised prolactin become likely |
These side effects follow from the map above. Blocking striatal D2 removes dopamine's support for movement. Blocking pituitary D2 releases prolactin.
Clozapine is the exception. It is the most effective antipsychotic for treatment-resistant illness and works at lower D2 occupancy, so D2 blockade is not the whole story.
#Medicines
| Medicine | Action | Used for |
|---|---|---|
| Haloperidol, risperidone, olanzapine and others | Block D2 | Psychosis, mania |
| Aripiprazole, brexpiprazole, cariprazine | Partly activate D2 and D3 | Psychosis, mania, add-on in depression |
| Pramipexole, ropinirole | Activate D2 and D3 | Parkinson's disease, restless legs |
| Metoclopramide | Blocks D2 in the gut and brainstem | Nausea |
#When it goes wrong
- Tardive dyskinesia. Years of D2 blockade can produce involuntary movements, thought to reflect receptors becoming oversensitive.
- Impulse control problems. D2 and D3 agonists can cause compulsive gambling, shopping or eating in some patients.
- Parkinson's disease. With dopamine lost, the no-go pathway dominates and movement becomes slow and hard to start.
#Serotonin receptors
Serotonin has the largest receptor family of any transmitter: at least 14 types in seven groups. This is why raising serotonin everywhere, as reuptake blockers do, produces so many different effects, wanted and unwanted.
#The receptors that matter most
| Receptor | Design | Where | What it does | Medicines |
|---|---|---|---|---|
| 5-HT1A | G protein, Gi | Raphe nuclei as autoreceptor; hippocampus, cortex | Slows serotonin neurons; calms receiving cells | Buspirone partly activates it |
| 5-HT1B, 5-HT1D | G protein, Gi | Nerve terminals, cranial blood vessels | Reduces transmitter release | Triptans activate them |
| 5-HT2A | G protein, Gq | Cortex, especially pyramidal neurons | Excites cortical cells; shapes perception | Second-generation antipsychotics block it; pimavanserin |
| 5-HT2C | G protein, Gq | Hypothalamus, limbic areas | Reduces appetite; restrains dopamine release | Blocked by olanzapine and mirtazapine |
| 5-HT3 | Ion channel | Brainstem vomiting centre, gut nerves | Triggers nausea and vomiting | Ondansetron blocks it |
| 5-HT4 | G protein, Gs | Gut, hippocampus | Speeds gut movement | Prucalopride activates it |
| 5-HT6, 5-HT7 | G protein, Gs | Cortex, hippocampus, thalamus | Cognition, body clock | None in wide use |
#Reading side effects from the map
A reuptake blocker raises serotonin at every receptor at once. Most early side effects trace to particular ones.
| Effect | Receptor most involved |
|---|---|
| Nausea | 5-HT3 |
| Early restlessness and poor sleep | 5-HT2A, 5-HT2C |
| Sexual side effects | 5-HT2A, 5-HT2C |
| Weight gain with olanzapine or mirtazapine | Blockade of 5-HT2C, with H1 |
Medicines that block some of these receptors while raising serotonin avoid some of these effects. Mirtazapine blocks 5-HT2 and 5-HT3 receptors, and causes little nausea or sexual dysfunction.
#Why antidepressants take weeks
One long-standing explanation involves the 5-HT1A autoreceptor. When a reuptake blocker raises serotonin, autoreceptors on raphe neurons detect it and slow those neurons down. Over two to four weeks the autoreceptors become less sensitive and firing recovers. Slower changes in brain plasticity also contribute.
#When it goes wrong, and current research
- Psychosis in Parkinson's disease. Pimavanserin reduces it by acting on 5-HT2A, without blocking dopamine receptors.
- Migraine. Triptans stop attacks through 5-HT1B and 5-HT1D.
- Heart valves. Long-term activation of 5-HT2B receptors damages heart valves. Several older medicines were withdrawn for this reason, and new drugs are screened against it.
- Clinical trials. Compounds that activate 5-HT2A are being studied under medical supervision for depression. They are not approved treatments in most countries.
#Adrenergic receptors
Adrenergic receptors read noradrenaline in the brain and both noradrenaline and adrenaline in the body. Three families do three different jobs, and each uses a different G protein.
#The three families
| Family | G protein | In the brain | In the body |
|---|---|---|---|
| Alpha-1 | Gq | Raises arousal and alertness | Narrows blood vessels, raises blood pressure |
| Alpha-2 | Gi | Brake on noradrenaline release; strengthens prefrontal focus | Lowers sympathetic outflow, heart rate and blood pressure |
| Beta (1, 2, 3) | Gs | Strengthens memory for emotional events | Beta-1 speeds the heart; beta-2 opens the airways |
#What they do
- Alpha-2 has two roles. On noradrenaline neurons it is the autoreceptor that slows release. On prefrontal neurons it strengthens the connections that hold information in working memory.
- The level decides which receptor wins. Moderate noradrenaline mainly engages alpha-2 receptors, which supports focus. High noradrenaline during stress also engages alpha-1 and beta receptors, which weaken prefrontal control and favour fast, habitual responses.
- Beta receptors tag memories. Noradrenaline acting on beta receptors in the amygdala makes emotionally charged events easier to remember.
#Medicines
| Medicine | Action | Used for |
|---|---|---|
| Guanfacine, clonidine | Activate alpha-2 | ADHD, high blood pressure |
| Prazosin | Blocks alpha-1 | High blood pressure; trauma-related nightmares |
| Propranolol | Blocks beta-1 and beta-2 | Tremor, physical symptoms of performance anxiety, migraine prevention |
| Mirtazapine | Blocks alpha-2, among other receptors | Depression |
#When it goes wrong
- ADHD. Guanfacine improves attention through prefrontal alpha-2 receptors, without raising transmitter levels.
- PTSD. Overactive noradrenaline signalling is linked to hyperarousal and nightmares.
- Dizziness as a side effect. Many antipsychotics and antidepressants also block alpha-1 receptors, which lets blood pressure fall on standing.
#Acetylcholine receptors
Acetylcholine has one receptor of each design. Nicotinic receptors are fast ion channels. Muscarinic receptors are slower G-protein receptors. The names come from the plant compounds first used to tell them apart.
#The two families
| Nicotinic | Muscarinic | |
|---|---|---|
| Design | Ion channel | G protein |
| Speed | Milliseconds | Hundreds of milliseconds and longer |
| Types | Muscle type; neuronal types, mainly alpha-4 beta-2 and alpha-7 | M1 to M5 |
| Main sites | Nerve-to-muscle junction, autonomic ganglia, brain | Brain, heart, glands, gut, bladder |
#Muscarinic subtypes
| Subtype | G protein | Where | What it does |
|---|---|---|---|
| M1 | Gq | Cortex, hippocampus | Supports memory and attention |
| M2 | Gi | Heart; autoreceptor in the brain | Slows the heart; brake on acetylcholine release |
| M3 | Gq | Glands, gut, bladder, eye | Saliva, gut movement, bladder contraction, pupil constriction |
| M4 | Gi | Striatum | Restrains dopamine release |
| M5 | Gq | Midbrain dopamine neurons | Less well understood |
#What they do
- Muscle. Every voluntary movement depends on nicotinic receptors at the nerve-to-muscle junction.
- Attention. Neuronal nicotinic receptors sit mostly on nerve terminals, where they increase the release of other transmitters.
- Memory. M1 receptors in the hippocampus and cortex support the storing of new information.
- Dopamine balance. M4 receptors in the striatum hold dopamine release in check.
#Medicines
| Medicine | Action | Used for |
|---|---|---|
| Xanomeline with trospium | Activates M1 and M4 in the brain; trospium blocks the effect in the body | Schizophrenia |
| Varenicline | Partly activates alpha-4 beta-2 nicotinic receptors | Smoking cessation |
| Oxybutynin and related drugs | Block M3 | Overactive bladder |
| Benztropine, trihexyphenidyl | Block muscarinic receptors in the brain | Tremor and stiffness caused by antipsychotics |
| Muscle relaxants used in surgery | Block nicotinic receptors on muscle | Anaesthesia |
#When it goes wrong
- Myasthenia gravis. Antibodies against muscle nicotinic receptors cause weakness that worsens with activity.
- Anticholinergic burden. Many common medicines block muscarinic receptors as a side effect. The combined load causes dry mouth, constipation, blurred vision and, in older adults, confusion and memory problems.
- Schizophrenia. Xanomeline with trospium, approved in 2024, is the first antipsychotic that does not act on dopamine receptors. Its effect is thought to come through M4 and M1.
#Histamine receptors
Histamine has four receptors, all G-protein receptors. Two matter in the brain: H1 keeps you awake, and H3 is the brake on histamine release.
#The four types
| Receptor | G protein | Where | What it does | Medicines |
|---|---|---|---|---|
| H1 | Gq | Brain, airways, blood vessels, skin | Wakefulness in the brain; allergy symptoms in the body | Antihistamines block it |
| H2 | Gs | Stomach lining | Acid release | Famotidine blocks it |
| H3 | Gi | Brain, as autoreceptor | Slows release of histamine and other transmitters | Pitolisant blocks it |
| H4 | Gi | Immune cells | Inflammation, itch | None in routine use |
#What to remember
- Why older antihistamines sedate. Diphenhydramine and similar drugs enter the brain and block H1 there. Newer antihistamines such as cetirizine and fexofenadine reach the brain much less.
- A common source of side effects. Several antipsychotics and antidepressants, including olanzapine, quetiapine and mirtazapine, block H1 strongly. This accounts for much of their sedation and weight gain.
- Blocking the brake promotes waking. Pitolisant blocks the H3 autoreceptor, so histamine neurons release more. It is used for the daytime sleepiness of narcolepsy.
- Low-dose sleep medicines. Doxepin at very low doses acts almost only on H1 and is used for insomnia.
#Opioid receptors
Opioid receptors read the body's own pain-relieving peptides: endorphins, enkephalins and dynorphins. All three types are Gi-coupled, so each one quiets the cell that carries it.
#The three types
| Receptor | Natural peptide | Where | What it does |
|---|---|---|---|
| Mu | Endorphins, enkephalins | Spinal cord, brainstem, thalamus, reward circuits, gut | Pain relief, reward, slowed breathing, slowed gut |
| Delta | Enkephalins | Cortex, limbic areas, spinal cord | Pain relief, mood regulation |
| Kappa | Dynorphins | Limbic areas, hypothalamus, spinal cord | Pain relief with low mood and unease; active during stress |
#How they work
Activating an opioid receptor does two things through Gi. On the sending side it closes calcium channels, so less transmitter is released. On the receiving side it opens potassium channels, so the cell is harder to excite. In pain pathways the combined effect is that fewer pain signals pass up the spinal cord.
#What they do
- Pain control. The brain has a descending system that turns pain signals down at the spinal cord, and it runs largely on mu receptors.
- Reward and bonding. Mu receptors contribute to the enjoyment of food, social contact and other rewards.
- Stress. Dynorphin acting on kappa receptors produces the low, uneasy state that follows prolonged stress.
- Breathing and the gut. Mu receptors in the brainstem slow breathing. Mu receptors in the gut wall slow its movement.
#Medicines
| Medicine | Action | Used for |
|---|---|---|
| Opioid pain medicines | Activate mu receptors | Severe acute pain, cancer pain, palliative care |
| Buprenorphine | Partly activates mu receptors | Opioid use disorder, pain |
| Naloxone | Blocks opioid receptors, fast and short-acting | Emergency reversal of opioid overdose |
| Naltrexone | Blocks opioid receptors, long-acting | Alcohol and opioid use disorders |
#When it goes wrong
- The main risk follows from the map. The same mu receptors that relieve pain also slow breathing. This is why overdose is dangerous and why naloxone saves lives.
- Tolerance and dependence. With repeated use the receptors and the cells behind them adapt. The same dose does less, and stopping suddenly causes withdrawal.
- Constipation. It comes from mu receptors in the gut and does not fade with tolerance.
- Research directions. Kappa receptor blockers are being studied for depression, on the reasoning that they would relieve stress-related low mood.
#Other receptors worth knowing
Four smaller receptor systems round out the picture. Each is the target of at least one widely used medicine or everyday substance.
| Receptor | Design | What it does | Acts on it |
|---|---|---|---|
| Glycine receptor | Ion channel, chloride | Fast inhibition in the spinal cord and brainstem | No medicine in routine use |
| Adenosine A1 | G protein, Gi | Quiets neurons as adenosine builds up through the day | Caffeine blocks it |
| Adenosine A2A | G protein, Gs | Promotes sleep; opposes dopamine D2 in the striatum | Caffeine blocks it; istradefylline blocks it in Parkinson's disease |
| Orexin OX1, OX2 | G protein | Hold wakefulness stable | Suvorexant, lemborexant and daridorexant block them for insomnia |
| Melatonin MT1, MT2 | G protein, Gi | Tell the body clock that it is night | Melatonin and ramelteon activate them |
#What to remember
- Caffeine is a receptor blocker. It occupies adenosine receptors and hides the fatigue signal. With regular use the brain adds adenosine receptors, which is why habitual users need more and feel tired when they stop.
- Two ways to treat insomnia. GABA-A medicines push the brain toward sleep by increasing inhibition. Orexin blockers remove the signal that holds wakefulness in place.
- Melatonin is a timing signal, not a sedative. It shifts the body clock. Its effect on how fast people fall asleep is modest.
#Patterns worth remembering
Six rules summarize the whole post.
- The receptor decides the effect. A transmitter is only a key. Whether the cell is excited, quieted or reshaped depends on the lock.
- Two designs, two timescales. Ion-channel receptors carry fast information. G-protein receptors change how the cell handles that information for seconds to minutes.
- Three G proteins predict direction. Gs and Gq activate, Gi quiets. Knowing the G protein tells you most of what a receptor does.
- Autoreceptors are brakes. Most are Gi-coupled and sit on the releasing cell. Drugs that block them raise release, and drugs that activate them lower it.
- Side effects are other receptors. Sedation, weight gain, dry mouth and dizziness usually come from a medicine also binding H1, muscarinic or alpha-1 receptors, not from its intended target.
- Receptors adapt. Numbers and sensitivity shift with sustained use. This explains tolerance, delayed benefit, and why many medicines are stopped gradually.
#Side effects by receptor
| Receptor blocked | Typical effect |
|---|---|
| Histamine H1 | Drowsiness, increased appetite |
| Muscarinic | Dry mouth, constipation, blurred vision, confusion in older adults |
| Alpha-1 adrenergic | Dizziness on standing |
| Dopamine D2 | Stiffness, restlessness, raised prolactin |
| Serotonin 5-HT2C | Increased appetite |
This table describes mechanisms. It is not treatment guidance.
#What this post leaves out
- Coverage. The brain has several hundred receptor types. Left out here are receptors for most neuropeptides, trace amines, purines other than adenosine, and all hormone receptors.
- Medicines only. The sections cover approved medicines. Non-medical drug use is outside the scope of this post.
- Simplified signalling. Many receptors couple to more than one G protein, pair up with other receptors, or signal through other routes. The one-line descriptions are starting points.
- Occupancy figures are averages. The D2 ranges come from imaging studies of groups. Individuals vary.
Nothing here is medical advice.
#Verification
This post was written from general knowledge and has not yet been checked against primary sources. Treat every figure as approximate until it is. Still to check:
- D2 occupancy ranges for antipsychotic effect and side effects
- GABA-A subunit roles: alpha-1 sedation, alpha-2 and alpha-3 anxiety relief, alpha-5 memory
- G-protein coupling for each receptor in the map
- Approval status of each medicine named
- The 5-HT1A autoreceptor account of delayed antidepressant response
- Trial outcomes for metabotropic glutamate receptor drugs